Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3073 The Role of Rb as a Prognostic Factor in Grade 3 Poorly Differentiated Neuroendocrine Carcinoma (G3NEC) Treated by First Line Platinum-Etoposide Combination, a Retrospective Study

Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,

Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,

#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling

Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hadoux J

Authors: Hadoux J, Afchain P, Walter T, Tougeron D, Hautefeuille V,

Keywords: neuroendocrine carcinoma, gastroenteropancreatic, chemotherapy, FOLFIRINOX, RB,

#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)

Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Couronne T, Fine C, Hadoux J, Lecomte T, Lorcet M,

Keywords: neuroendocrine, poorly differentiated neuroendocrine tumour, neuroendocrine carcinoma, chemotherapy, temozolomide, dacarbazine,

#1845 Mismatch Repair (MMR) Protein Expression is Uncommon in Poorly Differentiated Neuroendocrine Carcinoma

Introduction: Microsatellite instability (MSI) has been reported to occur in a significant proportion of neuroendocrine carcinoma (NEC) and mixed adenoneuroendocrine carcinomas (MANEC) (11 out of 89 cases, Sahnane et al, ERC 2015). It might be predictive of response to immunotherapy.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hadoux J

Authors: Hadoux J, Malka D, Berdeloux A, Planchard D, Boige V,

Keywords: Neuroendocrine carcinoma, mismatch repair, microsatellite instability,

#1672 PD-L1 Expression and Quantitative Assessment of Tumor-Infiltrating T Cell Subsets in Carcinoid Tumors and Large Cell Neuroendocrine Carcinomas of the Lung

Introduction: Little is known about the expression of PD-L1 an the immune infiltrate in neuroendocrine neoplasms of the lung.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Julien H

Authors: Kossai M, Hadoux J, Louvet E, Sullivan I, Thomas de Montpreville V,

Keywords: PD-L1, lung, neuroendocrine, immune infiltrate.,

Abstract Submissions for 2024

Abstract submissions for 2024 are now closed; all submitted abstracts are currently being reviewed by the abstract reviewing committee.

 

The 21st Annual ENETS Conference in 2024 provides the principal platform for NET researchers around the world to present their latest findings. ENETS will select the best abstracts submitted in both clinical and basic science and present these in sessions within the framework of its scientific programme.

 

Participants of the ENETS Conferences in 2023 can now access the abstract booklet, e-posters and videos, the poster carousel, and more via My ENETS.

Membership matters

Multidisciplinary is our credo. We welcome all NET-related disciplines and professionals! Learn more about the benefits of becoming an ENETS member.